ChromaDex (NASDAQ:CDXC) Posts Earnings Results, Beats Expectations By $0.01 EPS

ChromaDex (NASDAQ:CDXC) issued its earnings results on Tuesday. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.01, Zacks reports. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%.

ChromaDex Stock Performance

Shares of ChromaDex stock traded up $0.10 on Tuesday, hitting $5.60. The company’s stock had a trading volume of 1,094,356 shares, compared to its average volume of 379,956. The company has a market capitalization of $427.74 million, a price-to-earnings ratio of 560.56 and a beta of 2.21. ChromaDex has a 1 year low of $1.57 and a 1 year high of $7.97. The firm has a fifty day moving average price of $5.62 and a 200-day moving average price of $5.09.

Insiders Place Their Bets

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the sale, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.64% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on CDXC. StockNews.com upgraded ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 24th. Roth Mkm raised their target price on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, HC Wainwright boosted their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 4th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.